Cereno Scientific (Nasdaq First North: CRNO B), a biotech firm focused on innovative treatments for rare cardiovascular and pulmonary diseases, has announced a collaboration with PHA Europe & Global. This partnership is designed to advance patient-centered drug development, raise disease awareness, and improve outcomes for patients suffering from pulmonary arterial hypertension (PAH) and related conditions.
The collaboration will enable Cereno Scientific and PHA Europe & Global to systematically incorporate patient perspectives into clinical development programs. By integrating patient insights into study designs, the initiative aims to enhance the relevance and efficiency of clinical trials, ultimately leading to better engagement with patients globally. This effort aligns with Cereno’s broader strategy to address high unmet medical needs through disease-modifying therapies.
Sten R. Sörensen, CEO of Cereno Scientific, emphasized the value of patient input in developing new treatments, stating that their experiences are crucial for shaping clinical trial execution. Gerald Fischer, Managing Director of PHA Europe & Global, echoed this sentiment, highlighting the importance of ensuring the patient voice is central to clinical research. This collaboration not only aims to improve patient outcomes but also to foster greater awareness of the challenges faced by those living with pulmonary hypertension.
Use the database as your supply chain compass →
